Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

Exclusion Criteria

• •Previous treatment (within 90 days of screening) with monoclonal antibodies directed towards PCSK9
• •Secondary hypercholesterolemia, e.g. hypothyroidism or nephrotic syndrome
• •Homozygous familial hypercholesterolemia (HoFH)
• •Body weight \<16 kg at the screening and/or randomization (Day 1) visit
• •Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained alanine aminotransferase (ALT), aspartate aminotransferase (AST) elevation \>3x ULN, or total bilirubin elevation \>2x ULN (except patients with Gilbert's syndrome)
• •Pregnant or nursing females
• •Recent and/or planned use of other investigational medicinal products or devices